In vitro and in vivo characterization of 2-deoxy-2-18FFluoro-D- mannose as a tumor-imaging agent for PET

Journal of Nuclear Medicine

Volumn 54, Issue 8, 2013, Pages 1354-1361

  Furumoto, Shozo ^a,b   Shinbo, Ryo ^b   Iwata, Ren ^b   Ishikawa, Yoichi ^b   Yanai, Kazuhiko ^a   Yoshioka, Takashi ^c   Fukuda, Hiroshi ^b  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c YAMAGATA UNIVERSITY   (Japan)

Author keywords

18F fluorodeoxy mannose; Cancer; Hexokinase; PET; SN2 reaction

Indexed keywords

2 DEOXY 2 FLUOROMANNOSE F 18; GLUCOSE; HEXOKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CANCER DIAGNOSIS; CARBON NUCLEAR MAGNETIC RESONANCE; CELL DENSITY; CONTROLLED STUDY; DEPROTECTION REACTION; DIAGNOSTIC VALUE; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; ENZYME PHOSPHORYLATION; FLUORINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOACTIVITY; RAT; THIN LAYER CHROMATOGRAPHY; TUMOR CELL;

18F-FLUORODEOXY MANNOSE; CANCER; HEXOKINASE; PET; SN2 REACTION;

ANIMALS; BIOLOGICAL TRANSPORT; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; IODINE RADIOISOTOPES; LIVER NEOPLASMS; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOCHEMISTRY; RATS; RHAMNOSE;

EID: 84881458850     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.113571     Document Type: Article

References (28)

1. Bessell EM, Foster AB, Westwood JH. The use of deoxyfluoro-D- glucopyranoses and related compounds in a study of yeast hexokinase specificity. Biochem J. 1972;128:199-204.
2. Bessell EM, Thomas P. The deoxyfluoro-D-glucopyranose 6-phosphates and their effect on yeast glucose phosphate isomerase. Biochem J. 1973;131:77-82.
3. Sols A, Crane RK. Substrate specificity of brain hexokinase. J Biol Chem. 1954;210:581-595.
4. Som P, Atkins HL, Bandoypadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med. 1980;21:670-675.
5. 18F]-2-fluoro-2-deoxy-Dmannose- a new tracer for cancer detection. Eur J Nucl Med. 1982;7:294-297.
6. Kubota K. From tumor biology to clinical PET: a review of positron emission tomography (PET) in oncology. Ann Nucl Med. 2001;15:471-486.
7. Fischer BM, Mortensen J, Hojgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncol. 2001;2:659-666.
8. PoeppelTD,Krause BJ,HeusnerTA,BoyC, Bockisch A, Antoch G.PET/CTfor the staging and follow-up of patients with malignancies. EurJRadiol. 2009;70:382-392.
9. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(suppl 1):122S-150S.
10. Ido T, Wan CN, Casella V, et al. Labelled 2-deoxy-D-glucose analogs 18F-labelled 2-deoxy-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-mannose and 14C-2-deoxy-2-fluoro-D-glucose. J Labelled Comp Radiopharm. 1978;14:175-183.
11. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235-238.
12. 18F]fluoro- 2-deoxy-D-glucose and the influence of added carrier (KF) on FDG-synthesis. J Labelled Comp Radiopharm. 1986;23:1095-1097.
13. 18F]2-deoxy-2-fluoro-D-mannose. Int J Rad Appl Instrum [A]. 1986;37:409-413.
14. Binkley RW, Ambrose MG, Hehemann DG. Reactions of per-O-acetylated carbohydrate triflates with halide ions. J Carbohydr Chem. 1987;6:203-219.
15. 18F]2-fluoro-2- deoxy-D-glucose. Angew Chem Int Ed Engl. 2007;46:941-944.
16. 18F]FDM) as a tumor imaging agent. J Labelled Comp Radiopharm. 2011;54:S226.
17. 18F]FDM for tumor imaging. J Labelled Comp Radiopharm. 2009;52: S186.
18. 18F]acetylhypofluoride with glucals. Int J Appl Radiat Isot. 1984;36:111-115.
19. Odashima S. Establishment of ascites hepatomas in the rat, 1951-1962. Natl Cancer Inst Monogr. 1964;16:51-93.
20. Mizuta T, Kitamura K, Iwata H, et al. Performance evaluation of a high-sensitivity large-aperture small-animal PET scanner: ClairvivoPET. Ann Nucl Med. 2008;22:447-455.
21. Kubota K, Kubota R, Yamada S, Tada M, Takahashi T, Iwata R. Re-evaluation of myocardial FDG uptake in hyperglycemia. J Nucl Med. 1996;37:1713-1717.
22. Alexoff DL, Casati R, Fowler JS, et al. Ion chromatographic analysis of high specific activity 18FDG preparations and detection of the chemical impurity 2-deoxy-2-chloro-D-glucose. Int J Rad Appl Instrum [A]. 1992;43:1313-1322.
23. Kaarstad K, Bender D, Bentzen L, Munk OL, Keiding S. Metabolic fate of 18FFDG in mice bearing either SCCVII squamous cell carcinoma or C3H mammary carcinoma. J Nucl Med. 2002;43:940-947.
24. Kojima M, Kuribayashi S, Kanazawa Y, Haradahira T, Maehara Y, Endo H. Metabolic pathway of 2-deoxy-2-fluoro-D-glucose and 2-deoxy-2-fluoro-D-mannose in mice bearing sarcoma 180 studied by fluorin-19 nuclear magnetic resonance. Chem Pharm Bull (Tokyo). 1988;36:1194-1197.
25. Shimmura T, Nemoto M, Ino S, Kurami M. Metabolism of 18F-FDG (2-fluoro-2-deoxy-D-glucose) in tumor cells [in Japanese]. Kaku Igaku. 2003;40:31-38.
26. 18F]2-fluoro-2-deoxymannose using positron emission tomography. Nucl Med Biol. 1994;21:857-863.
27. 18F]2-fluoro-2-deoxy- D-mannose in patients with focal brain lesions. J Cereb Blood Flow Metab. 1991;11:485-491.
28. Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007;48:1468-1481. Technology